PMID- 22140464 OWN - NLM STAT- MEDLINE DCOM- 20120409 LR - 20211021 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 6 IP - 11 DP - 2011 TI - Epigenetic modulation of miR-122 facilitates human embryonic stem cell self-renewal and hepatocellular carcinoma proliferation. PG - e27740 LID - 10.1371/journal.pone.0027740 [doi] LID - e27740 AB - The self-renewal capacity ascribed to hESCs is paralleled in cancer cell proliferation, suggesting that a common network of genes may facilitate the promotion of these traits. However, the molecular mechanisms that are involved in regulating the silencing of these genes as stem cells differentiate into quiescent cellular lineages remain poorly understood. Here, we show that a differentiated cell specific miR-122 exemplifies this regulatory attribute by suppressing the translation of a gene, Pkm2, which is commonly enriched in hESCs and liver cancer cells (HCCs), and facilitates self-renewal and proliferation. Through a series of gene expression analysis, we show that miR-122 expression is highly elevated in quiescent human primary hepatocytes (hPHs) but lost or attenuated in hESCs and HCCs, while an opposing expression pattern is observed for Pkm2. Depleting hESCs and HCCs of Pkm2, or overexpressing miR-122, leads to a common deficiency in self-renewal and proliferation. Likewise, during the differentiation process of hESCs into hepatocytes, a reciprocal expression pattern is observed between miR-122 and Pkm2. An examination of the genomic region upstream of miR-122 uncovered hyper-methylation in hESCs and HCCs, while the same region is de-methylated and occupied by a transcription initiating protein, RNA polymerase II (RNAPII), in hPHs. These findings indicate that one possible mechanism by which hESC self-renewal is modulated in quiescent hepatic derivatives of hESCs is through the regulatory activity of a differentiated cell-specific miR-122, and that a failure to properly turn "on" this miRNA is observed in uncontrollably proliferating HCCs. FAU - Jung, Christine J AU - Jung CJ AD - Transplant Research Program, University of California Davis Medical Center, Sacramento, California, United States of America. cjjung@ucdavis.edu FAU - Iyengar, Sushma AU - Iyengar S FAU - Blahnik, Kimberly R AU - Blahnik KR FAU - Ajuha, Tijess P AU - Ajuha TP FAU - Jiang, Joy X AU - Jiang JX FAU - Farnham, Peggy J AU - Farnham PJ FAU - Zern, Mark AU - Zern M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20111128 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (3' Untranslated Regions) RN - 0 (MIRN122 microRNA, human) RN - 0 (MicroRNAs) RN - 0 (RNA, Messenger) RN - EC 2.7.7.- (RNA Polymerase II) SB - IM MH - 3' Untranslated Regions/genetics MH - Animals MH - Base Sequence MH - Carcinoma, Hepatocellular/*genetics/*pathology MH - Cell Differentiation/genetics MH - Cell Division MH - Cell Line, Tumor MH - Cell Proliferation MH - Chromatin Immunoprecipitation MH - DNA Methylation/genetics MH - Embryonic Stem Cells/*cytology/*metabolism MH - *Epigenesis, Genetic MH - Gene Expression Regulation, Neoplastic MH - Genome, Human/genetics MH - Hepatocytes/metabolism/pathology MH - Humans MH - Liver Neoplasms/genetics/*pathology MH - Mice MH - MicroRNAs/*genetics/metabolism MH - Molecular Sequence Data MH - Promoter Regions, Genetic/genetics MH - Protein Binding/genetics MH - Protein Biosynthesis MH - RNA Polymerase II/metabolism MH - RNA, Messenger/genetics/metabolism MH - Sequence Analysis, DNA PMC - PMC3225380 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2011/12/06 06:00 MHDA- 2012/04/10 06:00 PMCR- 2011/11/28 CRDT- 2011/12/06 06:00 PHST- 2011/02/16 00:00 [received] PHST- 2011/10/24 00:00 [accepted] PHST- 2011/12/06 06:00 [entrez] PHST- 2011/12/06 06:00 [pubmed] PHST- 2012/04/10 06:00 [medline] PHST- 2011/11/28 00:00 [pmc-release] AID - PONE-D-11-03488 [pii] AID - 10.1371/journal.pone.0027740 [doi] PST - ppublish SO - PLoS One. 2011;6(11):e27740. doi: 10.1371/journal.pone.0027740. Epub 2011 Nov 28.